Research news

The first ever treatment for the rare neurodegenerative disease Friedreich’s ataxia – for which UCLH and UCL led the UK trial – has been approved for use in the UK by the medicines’ regulator.

Congratulations to UCLH’s Dr Mary McCormack who has been listed as one of the 100 most influential people in health in the world by TIME magazine.

A new research project spearheaded by the CCTU at UCLH is trying to make more places on clinical trials available to young cancer patients aged between 16 and 24 years.

A new research project aims to improve understanding of the unique impact of health conditions on UK Black communities.

Newly reported updated results of a study from UCLH and UCL highlights the powerful benefits of a targeted immune therapy for a type of slow-growing blood cancer.